Erste Group Bank Has Pessimistic View of MRK FY2026 Earnings

Merck & Co., Inc. (NYSE:MRK) – Analysts at Erste Group Bank reduced their FY2026 earnings estimates for shares of Merck & Co., Inc. in a research note issued to investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $2.73 per share for the year, down from their prior estimate of $2.75. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $2.66 per share. Erste Group Bank also issued estimates for Merck & Co., Inc.’s FY2027 earnings at $9.47 EPS.

A number of other research analysts also recently issued reports on the company. Guggenheim increased their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Sanford C. Bernstein boosted their target price on Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research note on Tuesday, August 4th. Cantor Fitzgerald upped their price target on Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Royal Bank Of Canada reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a research report on Monday. Finally, Citigroup raised their price target on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research note on Monday. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $145.49 on Tuesday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm has a market cap of $358.94 billion, a price-to-earnings ratio of 116.39, a price-to-earnings-growth ratio of 6.58 and a beta of 0.21. The stock’s 50-day moving average is $144.25 and its 200-day moving average is $128.57. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 EPS. The company’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS.

Institutional Investors Weigh In On Merck & Co., Inc.

Several large investors have recently made changes to their positions in MRK. Dimensional Fund Advisors LP grew its holdings in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after purchasing an additional 2,969,856 shares during the period. Bank of America Corp DE raised its stake in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after buying an additional 2,919,780 shares during the period. Corient Private Wealth LLC raised its stake in Merck & Co., Inc. by 114.7% in the fourth quarter. Corient Private Wealth LLC now owns 5,210,548 shares of the company’s stock valued at $548,462,000 after buying an additional 2,783,482 shares during the period. Employees Provident Fund Board bought a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $254,206,000. Finally, Diamant Asset Management Inc. lifted its position in shares of Merck & Co., Inc. by 12,130.3% in the first quarter. Diamant Asset Management Inc. now owns 2,068,387 shares of the company’s stock valued at $248,806,000 after buying an additional 2,051,475 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced that first-time pivotal Phase 3 results from three oncology trials will be presented at the ESMO 2026 congress, alongside more than 90 additional abstracts covering over 20 tumor types. The disclosures create a near-term pipeline catalyst and could reinforce confidence in Merck’s ability to replenish growth as investors assess its longer-term portfolio. Merck ESMO 2026 announcement
• Positive Sentiment: Positive Phase 3 results from Merck’s personalized mRNA cancer-vaccine program with Moderna, combined with reports of a potential U.S.-backed initiative to accelerate cancer-vaccine development, support investor interest in the company’s oncology and vaccine pipeline.
• Neutral Sentiment: Industry reports project continued growth in bioconjugation reagents, bioprocessing supplies, industrial bioprocessing, protein labeling and cell culture. Merck is listed among suppliers in these markets, but the reports do not identify a new contract or quantify a material revenue impact for MRK. Global cell culture market report
• Neutral Sentiment: Citigroup raised its price target to $145 while maintaining a neutral rating, and RBC lowered its target to $145 with a sector-perform rating. The actions suggest limited near-term valuation upside at current levels.
• Negative Sentiment: Jefferies cut its peak-sales forecast for remigromig by 60% after detailed diabetic macular edema results showed smaller numerical vision gains and raised safety concerns versus established treatment Lucentis. Although the trial met the statistical non-inferiority threshold, the reduced commercial outlook weighs on expectations for Merck’s ophthalmology pipeline. Jefferies remigromig forecast

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.